糖尿病状态与慢性威胁性肢体缺血血运重建后长期死亡及大截肢结局
基于血管质量倡议注册库与医保理赔数据,纳入2014至2019年接受下肢旁路或外周血管介入的4218例慢性威胁性肢体缺血患者,经倾向评分1:1匹配分析。无论糖尿病状态,下肢旁路组5年死亡风险较外周血管介入组低26%;大截肢风险与血运重建方式无关,但糖尿病患者大截肢风险约为无糖尿病者的1.98倍。
要点
- 无论是否合并糖尿病,下肢旁路术后5年死亡风险较外周血管介入低26%(P交互=0.490)。
- 5年大截肢风险与血运重建方式无关(sHR 0.79,95%CI 0.57-1.08,P=0.140)。
- 糖尿病患者5年大截肢风险约为无糖尿病者的1.98倍(95%CI 1.55-2.54,P<.001)。
核心结论
- 糖尿病影响大多数慢性威胁性肢体缺血患者;无论糖尿病状态,下肢旁路术后5年死亡率低于外周血管介入。
- 下肢旁路与外周血管介入在5年大截肢风险上无差异,但糖尿病患者大截肢风险高于无糖尿病者。
- 作者认为需要在血运重建路径中提供共同决策、团队医疗和整合照护。
研究设计与样本
- 利用血管质量倡议注册库与医保理赔链接数据,纳入2014至2019年接受下肢旁路或外周血管介入的慢性威胁性肢体缺血患者。
- 共纳入4218例患者(年龄70.7±10.7岁,女性30.6%),其中62.3%有糖尿病。
- 采用倾向评分1:1匹配外周血管介入与下肢旁路队列,用Kaplan-Meier和Cox模型评估死亡累积发生率和风险比,用Aalen-Johansen和Fine-Gray模型评估大截肢累积发生率和亚分布风险比。
主要发现
- 无论糖尿病状态,下肢旁路组5年死亡累积发生率均低于外周血管介入组(无糖尿病组P=0.005,糖尿病组P=0.004)。
- 下肢旁路术后5年死亡风险较外周血管介入低26%,且与糖尿病状态无关(P交互=0.490)。
- 5年死亡风险与糖尿病状态无关联(HR 1.16,95%CI 0.99-1.34,P=0.060)。
- 无论糖尿病状态,下肢旁路与外周血管介入的5年大截肢累积发生率无差异(无糖尿病组P=0.955,糖尿病组P=0.955)。
- 5年大截肢风险与血运重建方式无关(sHR 0.79,95%CI 0.57-1.08,P=0.140);糖尿病患者大截肢风险为无糖尿病者的1.98倍(95%CI 1.55-2.54,P<.001),与治疗队列无关(P交互=0.869)。
临床怎么用
- 作者认为,在糖尿病患者的血运重建路径中需要共同决策、团队医疗和整合照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus (DM) affects over 60% of patients with chronic limb-threatening ischemia (CLTI). The association between DM and outcomes after lower-extremity bypass (LEB) or peripheral vascular interventions (PVI) remains unclear. Our study aims to assess the association between DM and 5-year all-cause mortality and major amputation after LEB vs PVI for CLTI. METHODS: Patients with CLTI who underwent LEB or PVI between 2014 and 2019 were studied using the Vascular Quality Initiative registry and stratified according to DM status. Outcomes were derived from linked Medicare claims data. Propensity score 1:1 matching between the PVI and LEB cohort was used. Cumulative incidence of mortality and hazard ratio (HR) were assessed with a Kaplan-Meier and Cox regression model, respectively. To account for the competing risk of death, major amputation was evaluated with the Aalen-Johansen and Fine-Gray model for cumulative incidence and sub-HR (sHR), respectively. The interaction between DM and PVI vs LEB was tested. RESULTS: Of 4218 patients were included (70.7 ± 10.7 years old, 30.6% female), 62.3% had DM. The 5-year cumulative incidence of death was lower in LEB vs PVI regardless of DM status (LEB vs PVI without DM: P = .005, and with DM: P = .004). The 5-year risk of death after LEB was 26% less than after PVI, regardless of DM status (P interaction = .490). There was no association between 5-year mortality risk and DM status (HR: 1.16, 95% confidence interval [CI]: 0.99-1.34, P = .060). The cumulative incidence of major amputation at 5 years did not differ in LEB vs PVI regardless of DM status (LEB vs PVI without the DM cohort: P = .955, and with the DM cohort: P = .955). The 5-year risk of major amputation was not associated with the type of revascularization (sHR: 0.79, 95% CI: 0.57-1.08, P = .140). Major amputation was twice higher in patients with DM than in those without DM (sHR: 1.98, 95% CI: 1.55-2.54, P < .001), regardless of treatment cohort (P interaction = 0.869). Similar results were seen regardless of insulin-dependent status. CONCLUSIONS: DM affects the majority of patients with CLTI. Regardless of DM status, mortality at 5 years was lower among patients who underwent LEB. There was no difference in major amputation in LEB vs PVI and mortality or major amputation at 5 years, but patients with DM had a higher risk of major amputation than those without DM. Shared decision-making, team-based care, and integrated care offerings are needed within the context of a revascularization pathway for patients with DM.
引用
- Callegari S, Romain G, Aggarwal A, et al. Diabetes status and long-term mortality and major amputation outcomes following revascularization in chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 40348290. doi:10.1016/j.jvs.2025.04.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。